Robust Sequential Revenue Growth Driven by
Fulfilled Demand
Inogen, Inc. (Nasdaq: INGN), a medical technology company
offering innovative respiratory products for use in the homecare
setting, today announced financial results for the quarter ended
June 30, 2022 and provided a business update.
Second Quarter 2022 Highlights
- Reported total revenue was $103.4 million for the period ended
June 30, 2022, representing a 1.8% increase from $101.6 million for
the period ended June 30, 2021.
- On a constant currency basis, total revenue for the period
ended June 30, 2022, increased 3.6% from $101.6 million for the
period ended June 30, 2021.
- Total revenue also represented a 28.6% increase from $80.4
million for the period ended March 31, 2022.
- GAAP net loss of $3.4 million, adjusted net loss of $0.4
million, and adjusted EBITDA was a positive $3.2 million.
- Strong balance sheet and cash position.
“We delivered solid performance in the quarter driven by our
ability to fulfill customer demand, while effectively managing
supply chain challenges and macro headwinds,” said Nabil Shabshab,
Inogen’s President and Chief Executive Officer. “We are also seeing
encouraging progress from our ongoing imperatives focused on
strengthening the foundations of the company while simultaneously
executing on our transformation. As we embark on the second half of
the year, we are actively managing supply chain challenges,
executing further on our strategic initiatives, and focusing on
productivity to position us for long-term, sustainable growth and
profitability. As a team, we are focused on our purpose of
improving lives through respiratory care.”
Second Quarter 2022 Financial Results
Second quarter total revenue increased 1.8% to $103.4 million
from $101.6 million in the second quarter of 2021, primarily driven
by higher international sales and domestic rentals, partially
offset by lower domestic business-to-business sales.
Total gross margin was 44.7% in the second quarter of 2022
versus 49.6% in the comparative period in 2021. The decline was
driven primarily by an increase in material prices and warranty
costs, partially offset by higher average selling price and
favorable sales channel mix.
Total operating expense for the quarter was $49.1 million
compared to $38.7 million in the second quarter of 2021,
representing an increase of 27.1%. The increased spend was
primarily due to a non-cash decrease in the benefit from the change
in fair value of the New Aera earnout liability and ongoing
strategic investments required to position the Company for
long-term sustainable growth.
GAAP net loss for the second quarter of 2022 was $3.4 million
compared to GAAP net income of $5.1 million during the second
quarter of 2021. Adjusted net loss was $0.4 million compared to
adjusted net income of $1.8 million during the second quarter of
2021.
Adjusted EBITDA was $3.2 million during the second quarter of
2022 compared to $12.4 million in the second quarter of 2021.
Cash and cash equivalents were $223.6 million as of June 30,
2022.
A reconciliation of adjusted EBITDA and adjusted net income
(loss) for the three and six months ended June 30, 2022 and 2021
are provided in the financial schedules that are a part of this
press release. An explanation of these non-GAAP financial measures
is also included below under the heading “Non-GAAP Financial
Measures.”
Third Quarter 2022 Financial Guidance
Inogen now projects revenue for the third quarter 2022 to be in
the range of approximately $97 million to $100 million, or
approximately 4% to 7% growth year-over-year.
Conference Call
Individuals interested in listening to the conference call today
at 2:00pm PT/5:00pm ET may do so by dialing:
US domestic callers (877) 841-3961
International callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live
webcast, please visit the Investor Relations section of Inogen’s
website at: http://investor.inogen.com/.
A replay of the call will be available beginning August 4, 2022,
at 4:00pm PT/7:00pm ET through 4:00pm PT/7:00pm ET on August 18,
2022. To access the replay, dial (877) 660-6853 or (201) 612-7415
and reference Conference ID: 13730720. The webcast will also be
available on Inogen’s website for one year following the completion
of the call.
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
About Inogen
Inogen is a medical technology company offering innovative
respiratory products for use in the homecare setting. The Company
primarily develops, manufactures and markets innovative portable
oxygen concentrators used to deliver supplemental long-term oxygen
therapy to patients suffering from chronic respiratory
conditions.
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements regarding the Company’s
expectations related to its financial and operational results for
the third quarter of 2022, expectations related to the second half
of 2022 for growth as well as supply chain challenges; and
expectations of future growth and profitability. Any statements
contained in this communication that are not statements of
historical fact may be deemed to be forward-looking statements.
Words such as “believes,” “anticipates,” “plans,” “expects,”
“will,” “intends,” “potential,” “possible,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to,
risks arising from the possibility that Inogen will not realize
anticipated revenue; risks related to the Company’s supply chain
and limited availability of parts used in our POCs, the risk of
further slowdowns or temporarily halts of production, or cost
inflation for such components; the impact of changes in
reimbursement rates and reimbursement and regulatory policies; the
possible loss of key employees, customers, or suppliers; expenses
and costs will exceed Inogen’s expectations; intellectual property
risks if Inogen is unable to secure and maintain patent or other
intellectual property protection for the intellectual property used
in its products. In addition, Inogen's business is subject to
numerous additional risks and uncertainties and information on
these and additional risks, uncertainties, and other information
affecting Inogen’s business operating results are contained in its
Annual Report on Form 10-K for the period ended December 31, 2021,
and in its other filings with the Securities and Exchange
Commission. Additional information will also be set forth in
Inogen’s Quarterly Report on Form 10-Q for the period ended June
30, 2022, to be filed with the Securities and Exchange Commission.
These forward-looking statements speak only as of the date hereof.
Inogen disclaims any obligation to update these forward-looking
statements except as may be required by law.
Non-GAAP Financial Measures
Inogen has presented certain financial information in accordance
with U.S. GAAP and also on a non-GAAP basis for the three and six
months ended June 30, 2022 and June 30, 2021. Management believes
that non-GAAP financial measures, taken in conjunction with U.S.
GAAP financial measures, provide useful information for both
management and investors by excluding certain non-cash and other
expenses that are not indicative of Inogen’s core operating
results. Management uses non-GAAP measures to compare Inogen’s
performance relative to forecasts and strategic plans, to benchmark
Inogen’s performance externally against competitors, and for
certain compensation decisions. Non-GAAP information is not
prepared under a comprehensive set of accounting rules and should
only be used to supplement an understanding of Inogen's operating
results as reported under U.S. GAAP. Inogen encourages investors to
carefully consider its results under U.S. GAAP, as well as its
supplemental non-GAAP information and the reconciliation between
these presentations, to more fully understand its business.
Reconciliations between U.S. GAAP and non-GAAP results are
presented in the accompanying tables of this release. For future
periods, Inogen is unable to provide a reconciliation of non-GAAP
measures without unreasonable effort as a result of the uncertainty
regarding, and the potential variability of, the amounts of
interest income, interest expense, depreciation and amortization,
stock-based compensation, provision for income taxes, and certain
other infrequently occurring items, such as acquisition-related
costs, that may be incurred in the future.
Consolidated Statements of
Comprehensive Income (Loss)
(unaudited)
(amounts in thousands, except
share and per share amounts)
Three months ended
Six months ended
June 30,
June 30,
2022
2021
2022
2021
Revenue
Sales revenue
$
89,291
$
90,304
$
156,693
$
167,385
Rental revenue
14,085
11,259
27,068
21,110
Total revenue
103,376
101,563
183,761
188,495
Cost of revenue
Cost of sales revenue
50,661
46,565
90,161
89,200
Cost of rental revenue, including
depreciation of $2,720 and $2,054, for the three months ended and
$5,358 and $3,942 for the six months ended, respectively
6,457
4,663
12,336
9,087
Total cost of revenue
57,118
51,228
102,497
98,287
Gross profit
46,258
50,335
81,264
90,208
Operating expense
Research and development
6,064
4,123
11,428
8,138
Sales and marketing
30,388
29,317
58,427
54,808
General and administrative
12,682
5,224
27,871
17,723
Total operating expense
49,134
38,664
97,726
80,669
Income (Loss) from operations
(2,876
)
11,671
(16,462
)
9,539
Other income (expense)
Interest income
225
29
254
86
Other income (expense)
(722
)
304
(1,155
)
(6
)
Total other income (expense),
net
(497
)
333
(901
)
80
Income (loss) before provision for
income taxes
(3,373
)
12,004
(17,363
)
9,619
Provision for income taxes
69
6,902
293
5,249
Net income (loss)
$
(3,442
)
$
5,102
$
(17,656
)
$
4,370
Other comprehensive income (loss), net
of tax
Change in foreign currency translation
adjustment
(634
)
123
(837
)
(334
)
Change in net unrealized gains (losses) on
foreign currency hedging
(1,204
)
390
(1,878
)
1,534
Less: reclassification adjustment for net
(gains) losses included in net income
606
(132
)
1,206
(373
)
Total net change in unrealized gains
(losses) on foreign currency hedging
(598
)
258
(672
)
1,161
Change in net unrealized gains (losses) on
marketable securities
7
(3
)
(1
)
1
Total other comprehensive income
(loss), net of tax
(1,225
)
378
(1,510
)
828
Comprehensive income (loss)
$
(4,667
)
$
5,480
$
(19,166
)
$
5,198
Basic net income (loss) per share
attributable to common stockholders (1)
$
(0.15
)
$
0.23
$
(0.77
)
$
0.20
Diluted net income (loss) per share
attributable to common stockholders (1)
$
(0.15
)
$
0.22
$
(0.77
)
$
0.19
Weighted-average number of shares used
in calculating net income (loss) per share attributable to common
stockholders:
Basic common shares
22,845,040
22,444,246
22,799,981
22,313,546
Diluted common shares
22,845,040
22,874,321
22,799,981
22,734,079
(1)
Reconciliations of net income (loss)
attributable to common stockholders basic and diluted can be found
in Inogen’s Quarterly Report on Form 10-Q to be filed with the
Securities and Exchange Commission.
(2)
Due to a net loss for the three and six
months ended June 30,2022, diluted loss per share is the same as
basic.
Consolidated Balance
Sheets
(unaudited)
(amounts in thousands)
June 30,
December 31,
2022
2021
Assets
Current assets
Cash and cash equivalents
$
223,621
$
235,524
Marketable securities
-
9,989
Accounts receivable, net
31,146
24,452
Inventories, net
33,496
31,873
Income tax receivable
1,670
1,343
Prepaid expenses and other current
assets
25,514
26,005
Total current assets
315,447
329,186
Property and equipment, net
40,418
38,926
Goodwill
32,803
32,979
Intangible assets, net
55,850
60,147
Operating lease right-of-use asset
23,484
24,912
Other assets
2,067
3,363
Total assets
$
470,069
$
489,513
Liabilities and stockholders'
equity
Current liabilities
Accounts payable and accrued expenses
$
26,808
$
25,689
Accrued payroll
12,659
17,307
Warranty reserve - current
7,360
6,480
Operating lease liability - current
3,506
3,393
Deferred revenue - current
9,007
8,568
Income tax payable
-
75
Total current liabilities
59,340
61,512
Warranty reserve - noncurrent
7,144
7,246
Operating lease liability - noncurrent
21,678
23,281
Earnout liability - noncurrent
13,975
15,386
Deferred revenue - noncurrent
11,395
11,861
Total liabilities
113,532
119,286
Stockholders' equity
Common stock
23
23
Additional paid-in capital
304,939
299,463
Retained earnings
51,616
69,272
Accumulated other comprehensive income
(loss)
(41
)
1,469
Total stockholders' equity
356,537
370,227
Total liabilities and stockholders'
equity
$
470,069
$
489,513
Condensed Consolidated Cash
Flow
(unaudited)
(amounts in thousands)
Six months ended June
30,
2022
2021
Cash flows from operating
activities
Net income (loss)
$
(17,656
)
$
4,370
Adjustments to reconcile net income (loss)
to net cash provided by (used in) operating activities:
Depreciation and amortization
11,608
10,339
Loss on rental units and other fixed
assets
1,466
601
Gain on sale of former rental assets
(93
)
(40
)
Provision for sales revenue returns and
doubtful accounts
6,200
5,266
Provision for rental revenue
adjustments
—
2,065
Provision for inventory losses
1,552
888
Stock-based compensation expense
5,685
5,755
Deferred income taxes
—
5,297
Change in fair value of earnout
liability
(1,411
)
(7,775
)
Changes in operating assets and
liabilities
(19,918
)
(6,637
)
Net cash provided by (used in) operating
activities
(12,567
)
20,129
Cash flows from investing
activities
Maturities of marketable securities
9,988
8,152
Investment in intangible assets
—
(101
)
Investment in property and equipment
(2,236
)
(3,594
)
Production and purchase of rental
equipment
(7,083
)
(7,957
)
Proceeds from sale of former assets
153
78
Net cash provided by (used in) investing
activities
822
(3,422
)
Cash flows from financing
activities
Proceeds from stock options exercised
35
9,958
Proceeds from employee stock purchases
915
927
Payment of employment taxes related to
release of restricted stock
(1,159
)
(545
)
Net cash provided by (used in) financing
activities
(209
)
10,340
Effect of exchange rates on cash
51
(159
)
Net increase (decrease) in cash and
cash equivalents
$
(11,903
)
$
26,888
Supplemental Financial
Information
(unaudited)
(in thousands, except units
and patients)
Three months ended
Six months ended
June 30,
June 30,
2022
2021
2022
2021
Revenue by region and category
Business-to-business domestic sales
$
11,212
$
27,558
$
16,313
$
58,301
Business-to-business international
sales
37,441
21,823
65,382
37,543
Direct-to-consumer domestic sales
40,638
40,923
74,998
71,541
Direct-to-consumer domestic rentals
14,085
11,259
27,068
21,110
Total revenue
$
103,376
$
101,563
$
183,761
$
188,495
Additional financial measures
Units sold
42,400
52,400
72,800
101,800
Net rental patients as of period-end
43,800
37,100
43,800
37,100
Reconciliation of U.S. GAAP to
Other Non-GAAP Financial Measures
(unaudited)
(in thousands)
Three months ended
Six months ended
June 30,
June 30,
Non-GAAP EBITDA and Adjusted
EBITDA
2022
2021
2022
2021
Net income (loss) (GAAP)
$
(3,442
)
$
5,102
$
(17,656
)
$
4,370
Non-GAAP adjustments:
-
Interest income
(225
)
(29
)
(254
)
(86
)
Provision for income taxes
69
6,902
293
5,249
Depreciation and amortization
5,848
5,241
11,608
10,339
EBITDA (non-GAAP)
2,250
17,216
(6,009
)
19,872
Stock-based compensation
3,020
3,239
5,685
5,755
Change in fair value of earnout
liability
(2,041
)
(8,082
)
(1,411
)
(7,817
)
Adjusted EBITDA (non-GAAP)
$
3,229
$
12,373
$
(1,735
)
$
17,810
Three months ended June
30,
Net Income (Loss)
Diluted EPS
Non-GAAP Adjusted Net Income (Loss) and
Diluted EPS
2022
2021
2022
2021
Financial Results (GAAP)
$
(3,442
)
$
5,102
$
(0.15
)
$
0.22
Non-GAAP adjustments:
Amortization of intangibles
2,150
2,203
Stock-based compensation
3,020
3,239
Change in fair value of earnout
liability
(2,041
)
(8,082
)
Income tax impact of adjustments (1)
(53
)
(634
)
Adjusted
$
(366
)
$
1,828
$
(0.02
)
$
0.08
Six months ended June
30,
Net Income (Loss)
Diluted EPS
Non-GAAP Adjusted Net Income (Loss) and
Diluted EPS
2022
2021
2022
2021
Financial Results (GAAP)
$
(17,656
)
$
4,370
$
(0.77
)
$
0.19
Non-GAAP adjustments:
Amortization of intangibles
4,297
4,467
Stock-based compensation
5,685
5,755
Change in fair value of earnout
liability
(1,411
)
(7,817
)
Income tax impact of adjustments (1)
(146
)
(577
)
Adjusted
$
(9,231
)
$
6,198
$
(0.40
)
$
0.27
(1)
Income tax impact of adjustments
represents the tax impact related to the non-GAAP adjustments
listed above and reflects an effective tax rate of -1.7% for 2022
and 24% for 2021.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220804005173/en/
Agnes Lee alee@inogen.net 650.677.9138
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024